Becton, Dickinson and Company (BD) and Suttons Creek have entered into a strategic collaboration to assist pharmaceutical and biotech firms in developing complex drug-device combination products. The partnership pairs ZebraSci—BD’s specialized testing organization—with Suttons Creek’s expertise in systems integration and product development strategy.
As pipelines increasingly incorporate biologics and GLP-1 therapies, the complexity of drug-device programs has surged. Development teams often struggle with fragmented workstreams across engineering, testing, and regulatory compliance when managing multiple vendors. This collaboration aims to improve coordination from the outset, reducing the risk of late-stage design changes and addressing potential FDA data requests stemming from misaligned testing strategies.
Executives from both firms highlighted that this model allows sponsors to maintain flexibility in technology selection while ensuring robust integration of key Design History File (DHF) deliverables. By aligning development strategy with data-driven testing early on, companies can accelerate decision-making and minimize delays caused by disconnected vendor handoffs, providing a more efficient path from concept to commercialization.